CelluPro's medium supports listing of first-in-class new drug Telitacicept

On March 9, 2021, Chinese National Medical Products Administration (NMPA) approved RemeGen’s first-in-class new drug Telitacicept. It is the first domestic new drug for systemic lupus erythematosus (SLE) listed in China in 60 years, which brings good news to Chinese patients with SLE.

Telitacicept is a TACI-Fc fusion protein targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), two cellular signaling molecules that regulate division and differentiation of B lymphocytes. With a novel drug structure and double target mechanism, Telitacicept can effectively suppress maturation and differentiation of B cells and reduce body’s immune response to treat autoimmune diseases.

The approval of Telitacicept marks CelluPro as the first domestic medium brand that supports listing of domestic new drug. As the long-term cooperation medium supplier of RemeGen, CelluPro would like to extend sincere congratulations on the good news.